EUVIMEDEUVIMED entdecken
Leitlinie

Recommendations on the health outcomes of infant formula supplemented with biotics by the ESPGHAN Special Interest Group on Gut Microbiota and Modifications

Ener Cagri Dinleyici iD, Flavia Indrio iD, Hania Szajewska iD, Iva Hojsak iD, Silvia Salvatore iD, Walter A Mihatsch iD, Roberto Berni Canani iD, Cristina Campoy iD, Magnus Domellöf iD, Ruggiero Francavilla iD, Alfredo Guarino iD, Pedro Gutierrez-Castrellón iD und 9 weitere

Journal of Pediatric Gastroenterology and Nutrition · 2026

DOI: 10.1002/jpn3.70195 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, 2026. Verfasst von Ener Cagri Dinleyici und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Eskisehir Osmangazi University Faculty of Medicine, Eskisehir, Turkey. Hauptthemen laut MEDLINE: Dietary Supplements, Gastrointestinal Microbiome, Infant Formula, Prebiotics. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 151 Literaturangaben. Gefördert von: None.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

For many years, biotics (including probiotics, prebiotics, human identical milk oligosaccharides, synbiotics, and postbiotics) have been added to infant formula to influence the gut microbiota of formula‐fed infants, aiming to bring it closer to that of breastfed infants. The Special Interest Group on Gut Microbiota and Modifications (SIG‐GMM) of the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) evaluated clinical outcomes from studies on biotic‐supplemented infant formulas. A modified Delphi process was used to establish consensus on recommendations. This document is supported by separately published technical reviews, which synthesize the available evidence, analyze its limitations, and identify research gaps. ESPGHAN SIG‐GMM concludes that infant formulas supplemented with one or more of the biotics evaluated so far fed to healthy infants do not raise safety concerns regarding growth, tolerance, and adverse effects. Based on available evidence, for some prebiotics (short‐chain galacto‐oligosaccharides/long‐chain fructo‐oligosaccharides), a weak recommendation in favor can be formulated because they soften stools by reducing stool consistency, and, to a lesser extent, increase stool frequency in presumed healthy infants. However, due to variability in study designs, intervention types, and measured outcomes, no clear conclusions can be drawn about their overall clinical benefits. Due to differences in interventions (e.g., duration, amount, and composition), inclusion criteria, and primary and secondary outcomes, for most biotics evaluated so far, no recommendations can actually be made “in favor” or “against.” This conclusion may reflect the limited data on specific biotics and outcomes because of the heterogeneity in the randomized controlled trials, rather than an actual lack of effect.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dietary SupplementsGastrointestinal MicrobiomeInfant FormulaPrebioticsProbioticsHumansInfantInfant, NewbornInfant Nutritional Physiological PhenomenaOligosaccharidesSynbioticsReview Literature as Topic

Stichwörter der Autor:innen

human milk oligosaccharidepostbioticprebioticprobioticsynbiotic

Substanzen

OligosaccharidesPrebiotics

Autor:innen und Institutionen

  • Department of Pediatrics, Eskisehir Osmangazi University Faculty of Medicine, Eskisehir, Turkey.
  • Department of Experimental Medicine, Pediatric Section, Medical School MedTech, University of Salento, Lecce, Italy.
  • Department of Paediatrics, The Medical University of Warsaw, Warsaw, Poland.
  • Children's Hospital Zagreb, University of Zagreb Medical School, Zagreb, Croatia.
  • Department of Medicine and Technological Innovation, Pediatrics, University of Insubria, Varese, Italy.
  • Department of Pediatrics, Ulm University, Ulm, Germany.

ORCID-Profile: Ener Cagri Dinleyici, Flavia Indrio, Hania Szajewska, Iva Hojsak, Silvia Salvatore, Walter A Mihatsch, Roberto Berni Canani, Cristina Campoy, Magnus Domellöf, Ruggiero Francavilla, Alfredo Guarino, Pedro Gutierrez-Castrellón, Nadja Haiden, Alexis Mosca, Rok Orel, Francesco Savino, Johannes B van Goudoever, Chris H P van den Akker, Zvi Weizman, Yvan Vandenplas

Förderung

  • None

Zitieren

APA

Dinleyici, E. C., Indrio, F., Szajewska, H., Hojsak, I., Salvatore, S., Mihatsch, W. A., Canani, R. B., Campoy, C., Domellöf, M., Francavilla, R., Guarino, A., Gutierrez-Castrellón, P., Haiden, N., Mosca, A., Orel, R., Savino, F., Shamir, R., van Goudoever, J. B., van den Akker, C. H. P., …, & Vandenplas, Y. (2026). Recommendations on the health outcomes of infant formula supplemented with biotics by the ESPGHAN Special Interest Group on Gut Microbiota and Modifications. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.70195

Vancouver

Dinleyici EC, Indrio F, Szajewska H, Hojsak I, Salvatore S, Mihatsch WA, et al. Recommendations on the health outcomes of infant formula supplemented with biotics by the ESPGHAN Special Interest Group on Gut Microbiota and Modifications. Journal of Pediatric Gastroenterology and Nutrition. 2026. doi:10.1002/jpn3.70195

BibTeX
@article{Dinleyici2026,
  author = {Dinleyici, Ener Cagri and Indrio, Flavia and Szajewska, Hania and Hojsak, Iva and Salvatore, Silvia and Mihatsch, Walter A and Canani, Roberto Berni and Campoy, Cristina and Domellöf, Magnus and Francavilla, Ruggiero and Guarino, Alfredo and Gutierrez-Castrellón, Pedro and Haiden, Nadja and Mosca, Alexis and Orel, Rok and Savino, Francesco and Shamir, Raanan and van Goudoever, Johannes B and van den Akker, Chris H P and Weizman, Zvi and Vandenplas, Yvan},
  title = {Recommendations on the health outcomes of infant formula supplemented with biotics by the ESPGHAN Special Interest Group on Gut Microbiota and Modifications},
  journal = {Journal of Pediatric Gastroenterology and Nutrition},
  year = {2026},
  doi = {10.1002/jpn3.70195}
}
Kostenlos starten →